Default Category
-
Gene Patents (A)
Hamermesh, Richard G.; Kiron, David; Andrews, PhillipCase HBS-811089-EEntrepreneurshipIn March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues deal with the potential implications of Judge Sweet's decision for biotechnology entrepreneurs and investors.Starting at €8.20
-
Innovating at AT&T: Partnering to Lead the Broadband Revolution
Applegate, Lynda M.; Andrews, Phillip; Herman, KerryCase HBS-812124-EEntrepreneurshipTo maximize their effectiveness, color cases should be printed in color. In 2010, the U.S. retail market value for next-generation non-handset wirelessly-enabled devices was just over $1 billion. By 2011 it had grown 1,141% to $13.2 billion and was forecast to reach $24.7 billion in 2015. At the same time, user demand for data was surging with the popularity of mobile Internet, e-mail, and messaging, which left carriers scrambling to increase net...Starting at €8.20
-
U.S. Universities and Technology Transfer
Hamermesh, Richard G.; Lerner, Josh; Andrews, PhillipCase HBS-812016-EEntrepreneurshipTechnology transfer from U.S. universities to industry has increased dramatically in the last 25 years. Reviews the history of technology transfer with particular emphasis on the Bayh-Dole Act of 1980. It then examines how universities responded to Bayh-Dole, the growth of technology transfer offices, and compares how three different universities (MIT, Stanford, and Harvard) approach technology transfer. Provides an overview of the technology tra...Starting at €8.20
-
Baroo (A): Pet Concierge
Eisenmann, Thomas R.; Ma, Susie L.Case HBS-820011-EEntrepreneurshipBaroo CEO Lindsay Hyde was facing unrest from the board of her pet services startup in August 2017. One board member (and lead investor) was alarmed that Baroo's growth was slowing while it's appetite for funding was accelerating. Hyde wanted to hit the gas and continue expanding to new cities, which meant she needed to raise venture capital. How could she convince the board and potential investors that the business opportunities were too good to...Starting at €8.20
-
Baroo (B)
Eisenmann, Thomas R.; Ma, Susie L.Case HBS-820026-EEntrepreneurshipBaroo CEO Lindsay Hyde must secure venture capital funding if she wants to save her pet services startup. If she is unable to finance a series A, she will need to sell or shut down.Starting at €5.74
-
MobSquad
Choudhury, Prithwiraj; Kerr, William R.; Ma, Susie L.Case HBS-821010-EEntrepreneurshipIrfhan Rawji (MBA 2004) launched MobSquad in October 2018 to help American tech start-ups retain hard-to-find talent, many of whom struggled with U.S. work visa issues, such as software engineers with experience in artificial intelligence, machine learning, or data science. MobSquad also helped companies fill open roles by tapping into its database of pre-vetted foreign tech workers. While there was growing demand for these specialists, the talen...Starting at €8.20
-
Gene Patents (B)
Hamermesh, Richard G.; Andrews, PhillipCase HBS-812130-EEntrepreneurshipThe case updates events since the Court's ruling against Myriad Genetics on March 29, 2010 and should be used in conjunction with Gene Patents (A). On July 29, 2011, a US Appeals Court reversed the prior ruling against Myriad. On September 16, 2011, the first major overhaul of US Patent law in nearly 60 years was signed into law. Among other provisions, the law moved the US to a first to-file priority when granting patents, as was the practice...Starting at €5.74
-
Companion Diagnostics: Uncertainties for Approval and Reimbursement
Hamermesh, Richard G.; Selby, Norman C; Andrews, PhillipCase HBS-813037-EEntrepreneurshipThe FDA approvals of novel therapeutics were seen as signs in the personalized medicine community of real progress in the growth of personalized medicine; The FDA's approval of such drugs, along with companion diagnostics, suggested a shift in thinking and regulatory practices at the agency. Beyond the regulatory questions, many considered the reimbursement system archaic, dispersed, unpredictable, and unnecessarily time consuming. Many questione...Starting at €8.20